BioNTech Investor Day Presentation Deck

BNT311 Anti-tumor activity (Phase 1 dose escalation part) 75 50 25 0 -25 -50 -75 IL T 1 PD PD PD PD PD PD PD mg mg mg 400 mg 11200 mg 50 mg 25 mg 25 140 80 PD 140 mg PD 200 mg PD PD SD SD SD 200 mg 1800 mg 200 mg 500 N N Best percent change from baseline in tumor size 140 mg 400 mg 140 mg 80 mg 140 mg 800 mg 800 mg 200 mg 80 mg 400 mg 50 mg 400 mg 80 mg 25 mg 140 mg 100 mg 200 mg 80 mg 1200 mg 800 mg 100 mg 1200 mg 80 mg 1200 mg 100 mg 400 mg -NE-SD-SD--SD-SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD PD SD SD SD SD SD SD SD PD PD SD SD SD NEa PR uPRbuPRD PR Dose level Data cut-off: September 29, 2020. Post-baseline scans were not conducted for five patients. A Minimum duration of response (5 weeks) per RECIST v1.1 not reached. B PR was not confirmed on a subsequent scan. 400 mg 800 mg 50 mg 50 mg 80 mg 200 mg 400 mg 400 mg Disease control achieved in 65.6% (40/61) of patients at a median of 3 months follow-up 4 early partial responses in TNBC (1), ovarian cancer (1), and CPI pre-treated NSCLC (2) patients Protein therapeutics NE, non-evaluable; NSCLC, non-small cell lung cancer; PD, progressive disease; PD-(L)1, programmed death (ligand) 1; PR, partial response; SD, stable disease; SoD, sum of diameters; uPR, unconfirmed partial response. Garralda E, et al. SITC Annual Meeting 2020; Poster presentation 412. Colorectal cancer NSCLC Ovarian cancer Pancreatic cancer Other cancer Prior PD-(L)1 800 mg 50 mg 400 mg 800 mg 200 mg 800 mg 80 mg 80 mg 200 mg 100 mg BIONTECH 119

View entire presentation